Interface membrane fibroblasts around aseptically loosened endoprostheses express MMP-13

Journal of Orthopaedic Research

Volumn 26, Issue 2, 2008, Pages 143-152

  Wagner, Susanne ^a   Gollwitzer, Hans ^b   Wernicke, Dirk ^c   Langer, Rupert ^d   Siebenrock, Klaus A ^e   Hofstetter, Willy ^f  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b BG UNFALLKLINIK MURNAU   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY OF BERN   (Switzerland)

^f UNIVERSITY OF BERN   (Switzerland)

Author keywords

Aseptic implant loosening; Bone degradation; Fibroblasts; Matrix metalloproteinase 13; Osteoclasts

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ALPHA1 COLLAGEN TYPE 1; CD68 ANTIGEN; COLLAGEN TYPE 1; COLLAGENASE 3; EDETIC ACID; EOSIN; HEMATOXYLIN; MESSENGER RNA; MONOCLONAL ANTIBODY; PARAFFIN; UNCLASSIFIED DRUG; CD68 ANTIGEN, HUMAN; COLLAGEN TYPE I, ALPHA 1 CHAIN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADULT; AGED; ARTHROPATHY; ARTICLE; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOPROSTHESIS LOOSENING; ENZYME SYNTHESIS; FEMALE; FIBROBLAST; GIANT CELL; HIP ARTHROPLASTY; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; KNEE ARTHROPLASTY; MACROPHAGE; MALE; MONOCYTE; NUCLEOTIDE SEQUENCE; OSTEOARTHRITIS; OSTEOCLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; REOPERATION; SYNOVIUM; TISSUE SECTION; BIOSYNTHESIS; CELL MEMBRANE; EXTRACELLULAR MATRIX; GENE EXPRESSION REGULATION; HIP PROSTHESIS; KNEE PROSTHESIS; METABOLISM; MIDDLE AGED; OSTEOLYSIS; PROSTHESIS FAILURE;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; BONE RESORPTION; CELL MEMBRANE; COLLAGEN TYPE I; EXTRACELLULAR MATRIX; FEMALE; FIBROBLASTS; GENE EXPRESSION REGULATION; HIP PROSTHESIS; HUMANS; KNEE PROSTHESIS; MACROPHAGES; MALE; MATRIX METALLOPROTEINASE 13; MIDDLE AGED; MONOCYTES; PROSTHESIS FAILURE;

EID: 38849126968     PISSN: 07360266     EISSN: None     Source Type: Journal    
DOI: 10.1002/jor.20494     Document Type: Article

References (40)

1. Takagi M, Santavirta S, Ida H, et al. 1998. Matrix metalloproteinases and tissue inhibitors of metalloproteinases in loose artificial hip joints. Clin Orthop Relat Res 352:35-45.
2. Willert HG, Semlitsch M. 1977. Reactions of the articular capsule to wear products of artificial joint prostheses. J Biomed Mater Res 11:57-164.
3. Affatato S, Bersaglia G, Rocchi M, et al. 2005. Wear behaviour of cross-linked polyethylene assessed in vitro under severe conditions. Biomaterials 26:3259-3267.
4. Sabokbar A, Kudo O, Athanasou NA. 2003. Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. J Orthop Res 21:73-80.
5. Ishiguro N, Ito T, Kurokouchi K, et al. 1996. mRNA expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in interface tissue around implants in loosening total hip arthroplasty. J Biomed Mater Res 32:611-617.
6. Campbell PA, Wang M, Amstutz HC, et al. 2002. Positive cytokine production in failed metal-on-metal total hip replacements. Acta Orthop Scand 73:506-512.
7. Stamenkovic I. 2003. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol 200:448-464.
8. Sato T, Foged NT, Delaisse JM. 1998. The migration of purified osteoclasts through collagen is inhibited by matrix metalloproteinase inhibitors. J Bone Miner Res 13:59-66.
9. Engsig MT, Chen QJ, Vu TH, et al. 2000. Matrix metalloproteinase 9 and vascular endothelial growth factor are essential for osteoclast recruitment into developing long bones. J Cell Biol 151:879-889.
10. Yokohama Y, Matsumoto T, Hirakawa M, et al. 1995. Production of matrix metallo-proteinases at the bone-implant interface in loose total hip replacements. Lab Invest 73:899-911.
11. Ma GF, Ali A, Verzijl N, et al. 2006. Increased collagen degradation around loosened total hip replacement implants. Arthritis Rheum 54:2928-2933.
12. Everts V, Delaisse JM, Korper W. 1998. Cysteine proteinases and matrix metalloproteiases play distinct roles in the subosteoclastic resorption zone. J Bone Miner Res 13:1420-1430.
13. Takei I, Takagi M, Santavirta S, et al. 2000. Messenger ribonucleic acid expression of 16 matrix metalloproteinases in bone-implant interface tissues of loose artificial hip joints. J Biomed Mater Res 52:613-620.
14. Andersen TL, Ovejero M, Kirkegaard T. 2004. A scrunity of matrix metalloproteinases in osteoclasts: evidence for heterogeneity and for the presence of MMPs synthesized by other cells. Bone 35:1107-1119.
15. Mirra JM, Amstutz HC, Matos M, et al. 1976. The pathology of the joint tissues and its clinical relevance in prosthesis failure. Clin Orthop Relat Res 117:221-240.
16. Mirra JM, Marder RA, Amstutz HC. 1982. The pathology of failed total joint arthroplasty. Clin Orthop Relat Res 170:175-183.
17. Wernicke D, Seyfert C, Hinzmann B, et al. 1996. Cloning of collagenase 3 from the synovial membrane and its expression in rheumatoid arthritis and osteoarthritis. J Rheumatol 23:590-595.
18. Genovese C, Rowe D, Kream B. 1984. Construction of DNA sequences complementary to rat alpha 1 and alpha 2 collagen mRNA and their use in studying the regulation of type I collagen synthesis by 1,25-dihydroxyvitamin D. Biochemistry 23:6210-6216.
19. Wagner S, Hofstetter W, Chiquet M, et al. 2003. Early osteoarthritic changes of human femoral head cartilage subsequent to femoro-acetabular impingement. Osteoarthritis Cartilage 11:508-518.
20. Delaisse JM, Boyde A, Maconnachie E, et al. 1987. The effects of inhibitors of cysteine-proteinases and collagenases on the resorptive activity of isolated osteoclasts. Bone 8:305-313.
21. Imai S, Konttinen YT, Jumppanen M, et al. 1998. High levels of expression of collagenase-3 (MMP-13) in pathological conditions associated with a foreign-body reaction. J Bone Joint Surg Br 80:701-710.
22. Delaisse JM, Eeckhout Y, Neff L, et al. 1993. (Pro)collagenase (matrix metalloproteinase-1) is present in rodent osteoclasts and in the underlying bone-resorbing compartment. J Cell Sci 106:1071-1082.
23. Dew G, Murphy G, Stanton H, et al. 2000. Localisation of matrix metalloproteinases and TIMP-2 in resorbing mouse bone. Cell Tissue Res 299:385-394.
24. Blavier L, Delaisse JM. 1995. Matrix metalloproteinases are obligatory for the migration of preosteoclasts to the developing marrow cavity of primitive long bones. J Cell Sci 108:3649-3659.
25. Fuller K, Chambers TJ. 1995. Localisation of mRNA for collagenase in osteocytic, bone surface and chondrocytic cells but not osteoclasts. J Cell Sci 108:2221-2230.
26. Delaisse JM, Andersen TL, Engsig MT, et al. 2003. Matrix metalloproteinases (MMP) and cathepsin K contribute differently to osteoclastic activities. Microsc Res Tech 61:504-513.
27. Everts V, Delaisse JM, Korper W, et al. 1992. Degradation of collagen in the bone-resorbing compartment underlying the osteoclast involves both cysteine-proteinases and matrix metalloproteinases. J Cell Physiol 150:221-231.
28. Koreny T, Tunyogi-Csapo M, Gal I, et al. 2006. The role of fibroblasts and fibroblast-derived factors in periprosthetic osteolysis. Arthritis Rheum 54:3221-3232.
29. Everts V, Korper W, Hoeben KA, et al. 2006. Osteoclastic bone degradation and the role of different cysteine proteinases and matrix metalloproteinases: differences between calvaria and long bone. J Bone Miner Res 21:1399-1408.
30. Golub LM, Ryan ME, Williams RC. 1998. Modulation of the host response in the treatment of periodontitis. Dent Today 17:102-109.
31. Hill PA, Murphy G, Docherty AJ, et al. 1994. The effects of selective inhibitors of matrix metalloproteinases (MMPs) on bone resorption and the identification of MMPs and TIMP-1 in isolated osteoclasts. J Cell Sci 107:3055-3064.
32. Westhoff CS, Freudiger D, Petrow P, et al. 1999. Characterization of collagenase 3 messenger RNA expression in the synovial membrane and synovial fibroblasts of patients with rheumatoid arthritis. Arthritis Rheum 42:1517-1527.
33. Lhotak S, Elavathil LJ, Vukmirovic-Popovic S, et al. 2000. Immunolocalization of matrix metalloproteinases and their inhibitors in clinical specimens of bone metastasis from breast carcinoma. Clin Exp Metastasis 18:463-470.
34. Ohshiba T, Miyaura C, Inada M, et al. 2003. Role of RANKL-induced osteoclast formation and MMP-dependent matrix degradation in bone destruction by breast cancer metastasis. Br J Cancer 88:1318-1326.
35. Winding B, NicAmhlaoibh R, Misander H, et al. 2002. Synthetic matrix metalloproteinase inhibitors inhibit growth of established breast cancer osteolytic lesions and prolong survival in mice. Clin Cancer Res 8:1932-1939.
36. Mandelin J, Li TF, Hukkanen M, et al. 2005. Interface tissue fibroblasts from loose total hip replacement prosthesis produce receptor activator of nuclear factor-kappaB ligand, osteoprotegerin and cathepsin K. J Rheumatol 32:713-720.
37. Ramage SC, Urban NH, Jiranek WA, et al. 2007. Expression of RANKL in osteolytic membranes: association with fibroblastic cell markers. J Bone Joint Surg Am 89:841-848.
38. Sabokbar A, Itonaga I, Sun SG, et al. 2005. Arthroplasty membrane-derived fibroblasts directly induce osteoclasts formation and osteolysis in aseptic loosening. J Orthop Res 23:511-519.
39. Kido A, Pap G, Nagler D, et al. 2004. Protease expression in interface tissues around loose arthroplasties. Clin Orthop 425:230-236.
40. Pap T, Pap G, Hummel KM, et al. 1999. Membrane-type-1 matrix metalloproteinase is abundantly expressed in fibroblasts and osteoclasts at the bone-implant interface of aseptically loosened joint arthroplasties in situ. J Rheumatol 26:166-169.